Search
for
Sort by
Research 31–60 of 1000+
- Epidermal growth factor receptor/mitogen-activated kinase inhibitor treatment induces a distinct inflammatory hair follicle response that includes collapse of immune privilege
- Acneiform eruptions caused by an epidermal growth factor receptor-tyrosine kinase inhibitor ZD 1839
- Nonscarring inflammatory alopecia associated with the epidermal growth factor receptor inhibitor gefitinib
- Scarring alopecia associated with the epidermal growth factor receptor inhibitor erlotinib
- Neutralization of IL-8 Prevents the Induction of Dermatologic Adverse Events Associated with the Inhibition of Epidermal Growth Factor Receptor
- Taiwanese Dermatological Association consensus for the prevention and management of epidermal growth factor receptor tyrosine kinase inhibitor-related skin toxicities
- Cutaneous Side Effects in Non-Small Cell Lung Cancer Patients Treated with Iressa (ZD1839), an Inhibitor of Epidermal Growth Factor
- Injury suppresses Ras cell competitive advantage through enhanced wild-type cell proliferation
- Cetuximab-Associated Elongation of the Eyelashes
- Erlotinib-Induced Skin Inflammation Is IL-1 Mediated in KC-Tie2 Mice and Human Skin Organ Culture
- 646 SOX4 is essential for melanoma tumorigenesis
- Hair follicle stem cells and the collapse of self-tolerance in alopecia: the interplay of barrier function, the microbiome, and immunity
- Trichomegaly of the eyelashes following treatment with cetuximab
- Fatal Toxic Epidermal Necrolysis Associated With Cetuximab in a Patient With Colon Cancer
- Trichoscopic Findings of Erosive Pustular Dermatosis of the Scalp Associated with Gefitinib
- PRIDE syndrome associated with panitumumab treatment – case report and literature review
- 1338 Epidermal growth factor receptor protects from immune privilege collapse and scarring hair follicle destruction
- Cetuximab Induced Hidrocystomas: A Case Report
- The relevance of collagen XVII expression in epidermal differentiation and proliferation
- Tumor Necrosis Factor-α and Interleukin-1 Antagonists Alleviate Inflammatory Skin Changes Associated with Epidermal Growth Factor Receptor Antibody Therapy in Mice
- A Case of Cicatricial Alopecia Associated with Erlotinib
- Gefitinib-induced hair alterations: Figure 1
- Dermatologic adverse events associated with chemotherapy and targeted anticancer therapy
- Severe scarring alopecia associated with combinational use of ficlatuzumab and gefitinib: a clinical and immunohistochemistry study
- Trichomegaly of the Eyelashes After Treatment with Erlotinib in Non-small Cell Lung Cancer
- An unusual terminal hair growth on the nose tip associated with gefitinib therapy
- Prevention of erlotinib-induced folliculitis with doxycycline
- Erosive Pustular Dermatosis of the Scalp-Like Eruption due to Gefitinib: Case Report and Review of the Literature of Alopecia Associated with EGFR Inhibitors
- Skin toxicity caused by EGFR antagonists—An autoinflammatory condition triggered by deregulated IL‐1 signaling?
- JAK-STAT1 as therapeutic target for EGFR deficiency-associated inflammation and scarring alopecia